# US 2008/0188566 A1 · Hydroxamic acid derivatives of 3-Phenyl propionic acids useful as therapeutic agents for treating anthrax poisoning

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0188566 A1
- Document ID: US20080188566A1
- Status: Published application
- Kind: A1
- Application number: 12/011,888
- Filed: 2008-01-30
- Published: 2008-08-07
- Earliest claimed: 2007-02-01
- Assignees: Pan Thera Biopharma,LLC
- Inventors: Alan T. Johnson; Guan-Sheng Jiao
- Web page: https://patentgrep.com/patent/US20080188566A1

## CPC

- C07C 259/06: having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
- A61P 31/04: Antibacterial agents
- A61P 39/02: Antidotes
- C07B 2200/07: Optical isomers
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Compounds having the formula wherein the symbols have the meaning described in the specification are hydroxamic acid derivatives of 3-phenyl-propionic acid and capable of inhibiting the lethal effects of infection by anthrax bacteria and are useful in the treatment of poisoning by anthrax.

## Claims

### Claim 1

A compound of the formula
where
R1 is F, Cl, Br, I, alkyl of 1-3 carbons, alkoxy of 1-3 carbons, thioalkoxy of 1-3 carbons, phenyl, O-phenyl, CN, CF3, OCF3; OH, NH2, NHC1-C6alkyl, N(C1-C6alkyl)2, CO2H or CO2(C1-C6 alkyl);
m is an integer having the value of 1 to 3;
R2 is alkyl of 1-9 carbons; C1-C6 alkylphenyl where phenyl is substituted with 0-3 R1 groups, C1-C6 alkylcyclohexyl, (CH2)nOR3, (CH2)nNHR4, NR4C1-C6alkyl, (CH2)nCF3, CH2OCH2phenyl;
(CH2)nNH(CH2)nR4, (CH2)nNR6R4, (CH2)nNR6(CH2)nR4, (CH2)nO(CH2)nR4, (CH2)nOR4, CN, phenyl substituted with 0 to 3 R1 groups, an alkenyl group having 2 to 9 carbons and one double bond,
n is an integer having the value of 1 to 8;
R3 is H, alkyl of 1 to 6 carbons, alkylphenyl where the alkylgroup has 1 to 6 carbons and the phenyl is substituted with 0-3 R1 groups;
R4 is H, alkyl of 1 to 10 carbons, (CH2)pcyclohexyl, C(O)alkyl of 1 to 4 carbons, C(O)alkylphenyl where the alkylgroup has 1 to 4 carbons and the phenyl is substituted with 0-3 R1 groups or with a 5 to 6 membered heteroayl group having 1 to 2 heteroatoms selected from O, S, and N, or with a 5 to 6 membered heteroaryl group having 1 to 2 heteroatoms selected from O, S and N and condensed with a phenylgroup, said heteroaryl or condensed heteroaryl group itself substituted with 0-3 R1 groups, or R4 is C(O)(CH2)pCOOH, (CH2)pphenyl where the phenyl is substituted with 0-3 R1 groups or with a NO2 group, or R4 is C(O)OC1-C6alkyl, or R4 is CH(CH3)phenyl where the phenyl is substituted with 0-3 R1 groups, or R4 is C(O)(CH2)pphenyl where the phenyl is substituted with 0-3 R1 groups, or R4 is C(O)CH(Ph)2, C(O)—CH2-(3PhO—)Ph, or R4 is a 5 to 6 membered heteroaryl group having 1 to 2 heteroatoms selected from O, S, and N, or a 5 to 6 membered heteroaryl group having 1 to 2 heteroatoms selected from O, S and N and condensed with a phenylgroup, said heteroaryl or condensed heteroaryl group itself substituted with 0-3 R1 groups, or R4 is CH2heteroaryl **CH2heteroaryl condensed with phenyl where the heteroaryl group is 5 or 6 membered and has 1 to 2 heteroatoms selected from O, S said heteroaryl group or condensed heteroaryl itself substituted with 0-3 R1 groups, or R4 is SO2-alkyl of 1 to 6 carbons, SO2-Ph where the phenyl is substituted with 0-3 R1 groups or with NO2 or with COOR5 group, or R4 is C(O)NH-alkylphenyl, or C(O)NH-phenyl where the alkyl group has 1 to 4 carbons and where the phenyl is substituted with 0-3 R1 groups;
p is an integer having the value of 0 to 4;
R5 is alkyl of 1 to 6 carbons or phenyl substituted with 0-3 R1 groups or with an OPh group;
R6 is alkyl of 1 to 6 carbons;
the asterisk indicates an asymmetric carbon, the wavy line represents a bond that can be in the R or in the S configuration,
or a pharmaceutically acceptable salt of said compound,
with the proviso that compounds selected from the group consisting of compounds identified below with structural formulas
are not included in the claim.

### Claim 2 (depends on 1)

A compound in accordance with claim 1 where R1 is selected independently from the group consisting of F, Cl, methyl, methoxy and phenyl.

### Claim 3 (depends on 2)

A compound in accordance with claim 2 where m is an integer having the value of 2 or 3.

### Claim 4 (depends on 3)

A compound in accordance with claim 3 where m is 2, one R1 group is methyl in the 3 (meta) position on the phenyl ring, and the other R1 group is fluoro in the 4 (para) position of the phenyl ring.

### Claim 5 (depends on 2)

A compound in accordance with claim 2 where m is 3, two R1 groups are methyl in the 3,3 (meta, meta) positions on the phenyl ring and the third R1 group is fluoro in the 4 (para) position of the phenyl ring.

### Claim 6

A compound of the formula
where the asterisk represents that the adjacent carbon is asymmetric and the wavy line represents a bond which can be of either R or S configuration, or a pharmaceutically acceptable salt of said compound.

### Claim 7

A compound of the formula
where
R1 is H or alkyl of 1 to 6 carbons;
R2 is H, CN, 4-Br-phenyl, alkyl of 1 to 8 carbons, alkenyl where the alkenyl group has 2 to 8 carbons and one double bond, (CH2)4—O—CH2-3Me-4F-phenyl or (CH2)6-4F-phenyl,
the asterisk represents that the adjacent carbon can be asymmetric and the wavy line represents a bond which can be of either R or S configuration,
or a pharmaceutically acceptable salt of said compound.

### Claim 8 (depends on 7)

A compound in accordance with claim 7 where R1 is H or methyl.

### Claim 9 (depends on 8)

A compound in accordance with claim 8 where R2 is H or methyl.

### Claim 10 (depends on 8)

A compound in accordance with claim 8 where R2 is 4-Br-phenyl, (CH2)4—O—CH2-3Me-4F-phenyl or (CH2)6-4F-phenyl,

### Claim 11 (depends on 8)

A compound in accordance with claim 8 where R2 is alkenyl.

### Claim 12

A compound of the formula
where
R1 is H or alkyl of 1 to 6 carbons;
R2 is (CH2)nNR6(CH2)p-phenyl, (CH2)nNH(CH2)pphenyl said phenyl groups being substituted with 0 to 3 groups selected from the group F, Cl and methyl, (CH2)nNH(CH2)pcyclohexyl, (CH2)nNH(CH2)pfuranyl, (CH2)nNH(CH2)ppyrazinyl, (CH2)nNH(CH2)p-2-benzo[b]thienyl said furanyl, pyrazinyl and 2-benzo[b]thienyl rings being substituted with 0 to 3 R1 groups
n is an integer having the value of 1 to 6,
p is an integer having the value of 0 to 4,
R6 is alkyl of 1 to 3 carbons,
the asterisk represents that the adjacent carbon can be asymmetric and the wavy line represents a bond which can be of either R or S configuration,
or a pharmaceutically acceptable salt of said compound.

### Claim 13 (depends on 12)

A compound in accordance with claim 12 where R1 is H or methyl.

### Claim 14 (depends on 13)

A compound in accordance with claim 13 where n is 4 and p is 1.

### Claim 15 (depends on 13)

A compound in accordance with claim 13 where n is 4 and R6 is methyl.

### Claim 16

A compound selected from the group of compounds consisting of
or a pharmaceutically acceptable salt of said compound.

### Claim 17

A compound of the formula
or a pharmaceutically acceptable salt of said compound.

### Claim 18

A compound of the formula
or a pharmaceutically acceptable salt of said compound.

### Claim 19

A pharmaceutical composition for the treatment of infection by bacillus anthraci in a mammal, including a human, adapted for systemic administration containing a pharmaceutically acceptable excipient and one or more compounds of the formula
where
R1 is F, Cl, Br, I, alkyl of 1-3 carbons, alkoxy of 1-3 carbons, thioalkoxy of 1-3 carbons, phenyl, O-phenyl, CN, CF3, OCF3; OH, NH2, NHC1-C6alkyl, N(C1-C6alkyl)2, CO2H or CO2(C1-C6 alkyl);
m is an integer having the value of 1 to 3;
R2 is alkyl of 1-9 carbons; C1-C6 alkylphenyl where phenyl is substituted with 0-3 R1 groups, C1-C6 alkylcyclohexyl, (CH2)nOR3, (CH2)nNHR4, NR4C1-C6alkyl, (CH2), CF3, CH2OCH2-phenyl;
(CH2), NH(CH2)nR4, (CH2), NR6R4, (CH2)nNR6(CH2)nR4, (CH2), O(CH2)nR4, (CH2)nOR4, CN, phenyl substituted with 0 to 3 R1 groups, an alkenyl group having 2 to 9 carbons and one double bond,
n is an integer having the value of 1 to 8;
R3 is H, alkyl of 1 to 6 carbons, alkylphenyl where the alkylgroup has 1 to 6 carbons and the phenyl is substituted with 0-3 R1 groups;
R4 is H, alkyl of 1 to 10 carbons, (CH2)pcyclohexyl, C(O)alkyl of 1 to 4 carbons, C(O)alkylphenyl where the alkylgroup has 1 to 4 carbons and the phenyl is substituted with 0-3 R1 groups or with a 5 to 6 membered heteroayl group having 1 to 2 heteroatoms selected from O, S, and N, or with a 5 to 6 membered heteroaryl group having 1 to 2 heteroatoms selected from O, S and N and condensed with a phenylgroup, said heteroaryl or condensed heteroaryl group itself substituted with 0-3 R1 groups, or R4 is C(O)(CH2)pCOOH, (CH2)pphenyl where the phenyl is substituted with 0-3 R1 groups or with a NO2 group, or R4 is C(O)OC1-C6alkyl, or R4 is CH(CH3)phenyl where the phenyl is substituted with 0-3 R1 groups, or R4 is C(O)(CH2)pphenyl where the phenyl is substituted with 0-3 R1 groups, or R4 is C(O)CH(Ph)2, C(O)—CH2-(3PhO—)Ph, or R4 is a 5 to 6 membered heteroaryl group having 1 to 2 heteroatoms selected from O, S, and N, or a 5 to 6 membered heteroaryl group having 1 to 2 heteroatoms selected from O, S and N and condensed with a phenylgroup, said heteroaryl or condensed heteroaryl group itself substituted with 0-3 R1 groups, or R4 is CH2heteroaryl **CH2heteroaryl condensed with phenyl where the heteroaryl group is 5 or 6 membered and has 1 to 2 heteroatoms selected from O, S said heteroaryl group or condensed heteroaryl itself substituted with 0-3 R1 groups, or R4 is SO2-alkyl of 1 to 6 carbons, SO2-Ph where the phenyl is substituted with 0-3 R1 groups or with NO2 or with COOR5 group, or R4 is C(O)NH-alkylphenyl, or C(O)NH-phenyl where the alkyl group has 1 to 4 carbons and where the phenyl is substituted with 0-3 R1 groups;
p is an integer having the value of 0 to 4;
R5 is alkyl of 1 to 6 carbons or phenyl substituted with 0-3 R1 groups or with an OPh group;
R6 is alkyl of 1 to 6 carbons;
the asterisk indicates an asymmetric carbon, the wavy line represents a bond that can be in the R or in the S configuration, or a pharmaceutically acceptable salt of said compound.

### Claim 20 (depends on 19)

A method of treating infection of a mammal, including a human being, by bacillus anthraci by administering to said mammal a pharmaceutical composition containing a pharmaceutically acceptable excipient and one or more compounds defined in claim 19.

### Claim 21 (depends on 19)

A method of inhibiting the lethal factor enzyme released by bacillus anthraci where such inhibition is needed, said method comprising contacting said enzyme with one or more compounds defined in claim 19.

### Claim 22 (depends on 19, 21)

A method in accordance with claim 21 where said contacting comprises administering to a human being infected by bacillus anthraci a pharmaceutical composition containing a pharmaceutically acceptable excipient and one or more compounds defined in claim 19.
